- Founded: 2016
- CEO: Andrew Krouse
- Size of Facility: 2000 sq ft
- Company Size: 15
- Funding Source: Grants (e.g. SBIR, CRCF, CIT), Investor Funded, Venture Captital/Private Equity
- Development Stage: Phase 1-2 Clinical Trials
Cavion, Inc. is a privately-held clinical-stage biotech company focused on developing first-in-class T-type calcium channel modulators to restore the brain’s natural rhythms in neurological diseases such as essential tremor, movement disorders and rare epilepsies.